Linear growth during growth hormone treatment in X-linked hypophosphatemic rickets: Report of two patients

Journal of Pediatric Endocrinology and Metabolism

Volumn 20, Issue SUPPL. 2, 2007, Pages 351-356

  Baroncelli, Giampiero I ^a   Bertelloni, Silvano ^a   Dati, Eleonora ^a   Cavallo, Luciano ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Growth hormone; Linear growth; X linked hypophosphatemic rickets

Indexed keywords

ALFACALCIDOL; CALCITRIOL; GROWTH HORMONE; HUMAN GROWTH HORMONE; PHOSPHATE;

ABSENCE OF SIDE EFFECTS; CASE REPORT; CLINICAL EXAMINATION; CONFERENCE PAPER; CONTROLLED STUDY; DATA ANALYSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GROWTH RATE; HUMAN; MALE; MEDICAL DOCUMENTATION; PATIENT COMPLIANCE; REFERENCE VALUE; SCHOOL CHILD; TREATMENT DURATION; VITAMIN D RESISTANT RICKETS;

EID: 34249896666     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Rasmussen H, Tenenhouse HS. Mendelian hypophosphatemias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995; 3717-3745.
2. DiMeglio LA, Econs MJ. Hypophosphatemic rickets. Rev Endocr Metab Disord 2001; 2: 165-173.
3. Marie PJ, Glorieux FH. Relation between hypomineralized periosteocytic lesions and bone mineralization in vitamin D-resistant rickets. Calcif Tissue Int 1983; 35: 443-448.
4. Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goodyer CG, Tenenhouse HS. Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 1997; 99: 1200-1209.
5. Ruchon AF, Marcinkiewicz M, Siegfried G, Tenenhouse HS, DesGroseillers L, Crine P, Boileau G. Pex mRNA is localized in developing mouse osteoblasts and odontoblasts. J Histochem Cytochem 1998; 46: 459-468.
6. Baroncelli GI, Bertelloni S, Sodini F, Galli L, Vanacore T, Fiore L, Saggese G. Genetic advances, biochemical and clinical features and critical approach to treatment of patients with X-linked hypophosphatemic rickets. Pediatr Endocrinol Rev 2004; 1: 361-379.
7. Glorieux FH, Marie PJ, Pettifor JM, Delvin EE. Bone response to phosphate salts, ergocalciferol and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med 1980; 303: 1023-1031.
8. Kruse K, Hinkel GK, Griefahn B. Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets. Eur J Pediatr 1998; 157: 894-900.
9. Makitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2003; 88: 3591-3597.
10. Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G. Effect of growth hormone treatment on final height, phosphate metabolism and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr 2001; 138: 236-243.
11. Haffner D, Nissel R, Wuhl E, Mehls O. Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics 2004; 113: e593-596.
12. Huiming Y, Chaomin W. Recombinant growth hormone therapy for X-linked hypophosphatemia in children. Cochrane Database Syst Rev 2005; 25: CD004447.
13. Ogle GD, Rosenberg AR, Kainer G. Renal effects of growth hormone. II. Electrolyte homeostasis and body composition. Pediatr Nephrol 1992; 6: 483-489.
14. Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, Di Nero G. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr 1993; 122: 37-45.
15. Seikaly MG, Brown R, Baum M. The effect of recombinant human growth hormone in children with X-linked hypophosphatemia. Pediatrics 1997; 100: 879-884.
16. Schutt SM, Schumacher M, Holterhus PM, Felgenhauer S, Hiort O. Effect of GH replacement therapy in two male siblings with combined X-linked hypophosphatemia and partial GH deficiency. Eur J Endocrinol 2003; 149: 317-321.
17. Gershberg H, Neumann LL, Mari S. Studies on vitamin D-resistant rickets; effects of human growth hormone. Metabolism 1964; 13: 636-649.
18. Lanes R, Harrison HE. Growth hormone therapy in a poorly growing child with hypophosphatemic rickets. J Endocrinol Invest 1990; 13: 833-837.
19. Wilson DM, Lee PD, Morris AH, Reiter EO, Gertner JM, Marcus R, Quarmby VE, Rosenfeld RG. Growth hormone therapy in hypophosphatemic rickets. Am J Dis Child 1991; 145: 1165-1170.
20. Haffner D, Wuhl E, Blum WF, Schaefer F, Mehls O. Disproportionate growth following long-term growth hormone treatment in short children with X-linked hypophosphataemia. Eur J Pediatr 1995; 154: 610-613.
21. Saggese G, Baroncelli GI, Bertelloni S, Perri G. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density. J Pediatr 1995; 127: 395-402.
22. Shaw NJ, Sharp C, Davie M. Growth hormone and hypophosphataemic rickets. Arch Dis Child 1995; 72: 543-544.
23. Reusz GS, Miltenyi G, Stubnya G, Szabo A, Horvath C, Byrd DJ, Peter F, Tulassay T. X-linked hypophosphatemia: effects of treatment with recombinant human growth hormone. Pediatr Nephrol 1997; 11: 573-577.
24. Saggese G, Baroncelli GI, Barsanti S. Growth hormone treatment of familial hypophosphatemic rickets. Arch Pediatr 1998; 5 (Suppl 4): 360S-363S.
25. Wilson DM, Olney RC, Tyerman G, Lee PDK, Klingensmith GJ, Chan JCM, Shah B, Shulman DI, Mahoney CP, Kaufman E. Growth hormone and X-linked hypophosphatemic rickets: five years of therapy. Bone 1998; 23: S652 (Abst).
26. Cameron FJ, Sochett EB, Daneman A, Kooh SW. A trial of growth hormone therapy in well-controlled hypophosphataemic rickets. Clin Endocrinol 1999; 50: 577-582.
27. Wilson DM. Growth hormone and hypophosphatemic rickets. J Pediatr Endocrinol Metab 2000; 13 (Suppl 2): 993-998.